Moderna (NASDAQ: MRNA) reported Q2 2026 revenue of $145 million, up about 2% from $142 million a year earlier, while GAAP loss per share narrowed to $1.97 from $2.13. Lower research and administrative spending helped reduce the net loss by 5%, although cash and investments declined by $600 million during the quarter. Pipeline developments were mixed, with an upcoming influenza vaccine decision and an inconclusive Phase 3 norovirus interim analysis.

Core financial results

Revenue was nearly unchanged year over year. Lower COVID-19 vaccine sales in the U.S. and South America were offset by deliveries under Moderna’s long-term U.K. government partnership and higher stand-ready manufacturing and collaboration revenue.

The quarterly loss narrowed as R&D and SG&A expenses declined. R&D spending fell following the wind-down of several late-stage programs, while the SG&A reduction reflected continued cost discipline.

Business and geographic performance

Moderna generated $87 million of revenue in the U.S. and $58 million in international markets. The geographic results reflected weaker COVID-19 vaccine sales in the U.S. and South America, partly balanced by U.K. deliveries under a long-term strategic government partnership.

Non-vaccine sources also contributed to the offset. The company reported higher stand-ready manufacturing and collaboration revenue, although it did not disclose separate amounts for those categories.

Profitability, cash flow and the balance sheet

Lower operating expenses reduced Moderna’s quarterly loss, but the company remained substantially loss-making relative to its current revenue base. R&D spending alone was $651 million, reflecting the continuing cost of advancing the pipeline even after several late-stage programs were wound down.

Cash, cash equivalents and investments fell from $7.5 billion at the end of March to $6.9 billion at June 30. Moderna attributed the decline primarily to funding operations, continued R&D investment and pipeline advancement.

The quarter-end balance did not reflect the $950 million litigation settlement payment made in July 2026. That subsequent payment is important when assessing liquidity alongside the company’s updated year-end cash outlook.

A near-term flu decision contrasts with a delayed norovirus program

Moderna’s late-stage pipeline produced two materially different developments. The company was awaiting an August 5 PDUFA decision for mFLUSIVA, its seasonal influenza vaccine candidate, which could become its fifth product if approved.

By contrast, mRNA-1403 did not meet the statistical criteria for early success in its Phase 3 interim analysis. Moderna is preparing to enroll an additional cohort, extending the work required to evaluate the norovirus vaccine candidate.

2026 guidance

Moderna reiterated its target of up to 10% revenue growth from 2025 while reducing two major cost forecasts. The company also raised its expected year-end cash and investment balance by approximately $0.2 billion.

Cost of sales includes a $0.9 billion non-recurring litigation settlement charge. Moderna also expects approximately $1.0 billion of SG&A expenses, $0.2 billion to $0.3 billion of capital expenditures and negligible full-year tax expense.

Revenue timing remains weighted toward the second half. The company expects approximately 55% of second-half revenue to be recognized in the third quarter, with the full-year geographic mix split approximately evenly between the U.S. and international markets. The year-end liquidity forecast excludes any additional drawdowns from the $0.9 billion still available under Moderna’s credit facility.

Recent insider transactions

The supplied six-month insider data reports 570,197 shares purchased across 30 transactions and 352,318 shares sold across eight transactions, resulting in net purchases of 217,879 shares. That net amount represented 0.80% of reported insider holdings of 28.96 million shares.

The latest records with a clearly identified transaction direction and reported value included derivative-security conversions and sales by President Stephen Hoge, as well as two transactions by officer Shannon Thyme Klinger. These transactions do not by themselves establish insiders’ views about the company’s outlook.

Risks investors need to monitor

• Continued losses and cash use: Q2 revenue remained small relative to R&D and administrative expenses, and cash and investments declined by $600 million during the quarter.
• Settlement-related liquidity pressure: The $950 million payment made after quarter-end was not reflected in the June 30 cash balance.
• Norovirus program uncertainty: mRNA-1403 did not meet the interim statistical threshold for early success, and Moderna must prepare an additional cohort.
• Commercial and regulatory dependence: Lower COVID-19 vaccine sales in the U.S. and South America required offsets from U.K. deliveries and other revenue, while the mFLUSIVA regulatory outcome remained pending at the reporting date.
• Revenue timing concentration: Moderna expects 55% of second-half revenue in the third quarter, making the timing of seasonal demand and deliveries important to its full-year target.

Summary

Moderna’s Q2 2026 revenue was nearly flat, but lower R&D and SG&A expenses helped narrow its net loss. The company improved its cost and year-end liquidity outlook while maintaining its revenue growth target, though continued cash use and the post-quarter settlement payment remain significant. The next major operating signals are the mFLUSIVA regulatory decision, progress on the expanded norovirus study and execution against the seasonally weighted second-half revenue plan.

Find out more